Influencing factors for FibroTouch measurements in chronic hepatitis B patients based on liver pathology

Li ZhengXin; Chen YangYi; Zhao ZhiMin; Lyu Jing; Chen GaoFeng; Liu ChengHai

doi:10.3969/j.issn.1001-5256.2019.02.019

Volume 35 Issue 2

Feb. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(2): 338-344

PDF( 2015 KB)

Influencing factors for FibroTouch measurements in chronic hepatitis B patients based on liver pathology

DOI: 10.3969/j.issn.1001-5256.2019.02.019

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Published Date: 2019-02-20

Abstract

Abstract

Objective To investigate the changes in positive staining of CD34, CK7, and CK19 and amount of fibrous collagen deposition in patients with chronic hepatitis B ( CHB) and the pathological basis affecting FibroTouch measurements. Methods A retrospective analysis was performed for the clinical data of 72 CHB patients who visited Department of Liver Cirrhosis in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2015 to December 2017. The amount of positive immunohistochemical staining of CD34, CK7, and CK19 was calculated, as well as the amount of fibrous collagen deposition in Masson trichrome staining and liver stiffness measurement ( LSM) by FibroTouch. The t-test was used for comparison of normally distributed continuous data between two groups. The Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data or continuous data with heterogeneity of variance between two groups. The chi-square test was used for comparison of categorical data between groups, and the Kruskal-Wallis H test was used for comparison of ranked data between multiple groups. The receiver operating characteristic ( ROC) curve was used to analyze the value of LSM in the diagnosis of hepatitis B cirrhosis, and the logistic regression model was used for multivariate analysis. Results With the increase in inflammation degree, there was no significant change in the amount of positive staining of CD34 ( P > 0. 05) , while there were significant increases in the amount of positive staining of CK19 and the amount of fibrous collagen deposition ( H = 9. 02 and 14. 12, P =0. 011 and 0. 001) . With the progression of liver fibrosis, there were significant increases in the amount of positive staining of CD34 and CK7 and the amount of fibrous collagen deposition ( H = 10. 26, 16. 29, and 22. 97, P = 0. 016, 0. 001, and < 0. 001) . The logistic regression analysis showed that the amount of positive staining of CK7 ( Wald = 4. 756, P = 0. 029) and the amount of fibrous collagen deposition ( Wald = 4. 757, P = 0. 029) were independent influencing factors for FibroTouch measurements. Conclusion Increases in the amount of fibrous collagen deposition and the amount of positive staining of CK7 may lead to increased FibroTouch measurements.
- hepatitis B, chronic,
- liver cirrhosis,
- FibroTouch,
- risk factors

FullText(HTML)

References(26)

References

[1]JIN CT, GUO LW, LIANG WF.Research progress on non-invasive serum markers for liver fibrosis assessment in patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:E-lectronic Edition, 2018, 12 (1) :11-14. (in Chinese) 金彩婷, 郭利伟, 梁伟峰.慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展[J/CD].中华实验和临床感染病杂志:电子版, 2018, 12 (1) :11-14.

[2]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J].Hepatol Int, 2016, 10 (1) :1-98.

[3]VIZZUTTI F, ARENA U, ROMANELLI RG, et al.Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis[J].Hepatology, 2007, 45 (5) :1290-1297.

[4]de LDINGHEN V, WONG VW, VERGNIOL J, et al.Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement:Comparison between M and XL probe of FibroScan (R) [J].JHepatol, 2012, 56 (4) :833-839.

[5]CHON YE, CHOI EH, SONG KJ, et al.Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B:A meta-analysis[J].PLo S One, 2012, 7 (9) :e44930.

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[7]WANG TL, LIU X, ZHOU YP, et al.A semiquantitative scoring system for assessment of hepatic inflammation and fibrosis in chronic viral hepatitis[J].Chin J Hepatol, 1998, 6 (4) :5-7. (in Chinese) 王泰龄, 刘霞, 周元平, 等.慢性肝炎炎症活动度及纤维化程度计分方案[J].中华肝脏病杂志, 1998, 6 (4) :5-7.

[8]ABDALLA AF, ZALATA KR, ISMAIL AF, et al.Regression of fibrosis in paediatric autoimmune hepatitis:Morphometric assessment of fibrosis versus semiquantiatative methods[J].Fibrogenesis Tissue Repair, 2009, 2 (1) :2.

[9]BEDOSSA P.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology, 2014, 60 (2) :565-575.

[10]STUECK AE, WANLESS IR.Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis[J].Hepatology, 2015, 61 (5) :1696-1707.

[11]THEISE ND, SAXENA R, PORTMANN BC, et al.The canals of Hering and hepatic stem cells in humans[J].Hepatology, 1999, 30 (6) :1425-1433.

[12]ROSKAMS TA, THEISE ND, BALABAUD C, et al.Nomenclature of the finer branches of the biliary tree:Canals, ductules, and ductular reactions in human livers[J].Hepatology, 2004, 39 (6) :1739-1745.

[13]LIN WR, LIM SN, MCDONALD SA, et al.The histogenesis of regenerative nodules in human liver cirrhosis[J].Hepatology, 2010, 51 (3) :1017-1026.

[14]YOON SM, GERSIMIDOU D, KUWAHARA R, et al.Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans[J].Hepatology, 2011, 53 (3) :964-973.

[15]FALKOWSKI O, AN HJ, IANUS IA, et al.Regeneration of hepatocyte'buds'in cirrhosis from intrabiliary stem cells[J].J Hepatol, 2003, 39 (3) :357-364.

[16]GUIDO M, SARCOGNATO S, SONZOGNI A, et al.Obliterative portal venopathy without portal hypertension:An underestimated condition[J].Liver Int, 2016, 36 (3) :454-460.

[17]OHBU M, OKUDAIRA M, WATANABE K, et al.Histopathological study of intrahepatic aberrant vessels in cases of noncirrhotic portal hypertension[J].Hepatology, 1994, 20 (2) :302-308.

[18]GUIDO M, SARCOGNATO S, RUSSO FP, et al.Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis[J].Liver Int, 2018, 38 (10) :1770-1776.

[19]DEFFIEUX T, GENNISSON JL, BOUSQUET L, et al.Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography[J].J Hepatol, 2015, 62 (2) :317-324.

[20]CASSINOTTO C, BOURSIER J, LEDINGHEN V, et al.Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy[J].Hepatology, 2016, 63 (3) :1817-1827.

[21]SADLER MD, CROTTY P, FATOVICH L, et al.Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis[J].Can J Gastroenterol Hepatol, 2015, 29 (3) :139-144.

[22]RAMZY I, ELSHARKAWY A, FOUAD R, et al.Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients[J].Acta Trop, 2017, 176:283-287.

[23]LENG XJ, YAN XB.Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J].J Clin Hepatol, 2018, 34 (9) :1891-1895. (in Chinese) 冷雪君, 颜学兵.FibroTouch对不同BMI水平非酒精性脂肪性肝病患者肝纤维化程度的评估比较[J].临床肝胆病杂志, 2018, 34 (9) :1891-1895.

[24]LI JB, LIU S, WEN B, et al.Clinical significance of FibroTouch, ultrasound, and computed tomography in diagnosis of fatty liver disease:A comparative analysis[J].J Clin Hepatol, 2016, 32 (3) :459-462. (in Chinese) 李静波, 刘姝, 温博, 等.FibroTouch与B超、CT对脂肪肝的诊断价值比较[J].临床肝胆病杂志, 2016, 32 (3) :459-462.

[25]Review Panel for Liver Stiffness Measurement.Recommendations for the clinical application of transient elastography in liver fibrosis assessment[J].Chin J Hepatol, 2013, 21 (6) :420-424. (in Chinese) 肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志, 2013, 21 (6) :420-424.

[26]JIA J, HOU J, DING H, et al.Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2015, 30 (4) :756-762.

Relative Articles

[1]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[2]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[3]	Shanshan LI, Manman XU, Zhongping DUAN, Yu CHEN. Risk factors for liver cirrhosis in acute-on-chronic liver failure patients without liver cirrhosis in the convalescence stage[J]. Journal of Clinical Hepatology, 2021, 37(12): 2824-2829. doi: 10.3969/j.issn.1001-5256.2021.12.019
[4]	Min WANG, Wenping LUO, Guanhua ZHANG, Xinyan ZHAO, Hong MA, Ying TIAN, Yu WANG. Diagnostic value of FibroTouch, FibroScan, and acoustic radiation force impulse for liver fibrosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(4): 817-822. doi: 10.3969/j.issn.1001-5256.2021.04.019
[5]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[6]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[7]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[8]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[9]	Zhao XiaoBo, Yu Jing, Zhang ZhenHua, Zou GuiZhou. Stability of FibroTouch in determining liver stiffness measurement and controlled attenuation parameter[J]. Journal of Clinical Hepatology, 2020, 36(1): 102-106. doi: 10.3969/j.issn.1001-5256.2020.01.023
[10]	Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016
[11]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[12]	Leng XueJun, Yan XueBing. Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J]. Journal of Clinical Hepatology, 2018, 34(9): 1891-1895. doi: 10.3969/j.issn.1001-5256.2018.09.013
[13]	Yu ZhiRui, Wei GuoXi, Liu QiChang, Jin PeiMin. Risk factors for HBV-related liver cirrhosis complicated by acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(5): 860-863. doi: 10.3969/j.issn.1001-5256.2017.05.013
[14]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[15]	Yang Hua, Liu YunXia, Li Peng, Yang ShaoQi, Wang YuanZhen. Analysis of risk factors for early rebleeding from esophageal and gastric varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 540-542. doi: 10.3969/j.issn.1001-5256.2014.06.015
[16]	Shi MeiJie, Zhang ChaoZhen, Chi XiaoLing, Xie YuBao, Xiao HuanMing. Analysis of clinical high-risk factors for hepatitis B cirrhosis confirmed by liver biopsy[J]. Journal of Clinical Hepatology, 2014, 30(2): 149-152. doi: 10.3969/j.issn.1001-5256.2014.02.013
[17]	Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021
[18]	Wu Na, Zhang MingYuan, Wu RuiHong, Zhang YingWen, Jin JingLan, Zhu YingQiao, Niu JunQi. Diagnostic values of FibroScan and FibroTouch for liver fibrosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2014, 30(7): 624-627. doi: 10.3969/j.issn.1001-5256.2014.07.012
[19]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	王鲜庭，程贤文，王新磊. 双重血浆置换术联合补肝利脂汤治疗重度高甘油三酯血症合并非酒精性脂肪性肝病患者的疗效分析. 国际医药卫生导报. 2024(24): 4186-4191 .
2.	贺国华，刘林，赵强，李婷，张玉洁. 瞬时弹性成像评估不同程度脂肪肝的临床价值. 临床超声医学杂志. 2023(03): 233-236 .
3.	郭声，刘长虹，刘颖，廖燕，魏应凤. 水飞蓟宾治疗慢性乙型病毒性肝炎临床研究. 光明中医. 2023(24): 4736-4739 .
4.	张鹭坚，蔡梅真. 肝炎肝硬化患者血清总胆固醇、血清白蛋白与胆碱酯酶水平在肝功能评估中的应用. 吉林医学. 2022(02): 482-484 .
5.	胡晓菊. 血清ALB、CHE、ALT、γ-GT水平检测在肝硬化诊断中的应用价值. 中国民康医学. 2022(21): 116-118 .
6.	陈雅洁，李昭贤，王洋，曹经琳，窦剑. 瞬时弹性成像技术在肝移植围手术期应用的研究进展. 中华器官移植杂志. 2021(08): 501-504 .
7.	李洁，杨晓青，齐素艳，王立美，冯苏. 二维实时剪切波弹性成像诊断慢性肝病肝纤维化的危险因素分析. 河北医药. 2021(23): 3578-3581 .
8.	聂逢兵. 肝炎肝硬化诊断中肝功能四项联合检测的临床应用. 中外医学研究. 2020(04): 44-46 .
9.	刘旭东，赵壮志，吕萍，徐新杰，赵晓芳. FibroTouch诊断慢性乙型肝炎肝纤维化的影响因素及临床价值. 中西医结合肝病杂志. 2020(03): 261-264 .
10.	蔡庆贤，罗芳，夏章，吴其恺，陈凤娟. FibroScan(R)实施受控衰减参数在慢性HBV感染者中诊断非酒精性脂肪性肝病的价值. 国际医药卫生导报. 2020(12): 1693-1696 .
11.	张志安，吴飞燕，钟培星. Fibro Touch脂肪衰减参数在乙型肝炎合并非酒精性脂肪肝中的应用价值. 深圳中西医结合杂志. 2019(11): 60-62 .
12.	吕艳杭，吴姗姗，王振常. 阿德福韦酯联合柔肝化纤颗粒治疗慢性乙型肝炎肝硬化临床效果. 中国医药导报. 2019(32): 107-110 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1787) PDF downloads(297)

Influencing factors for FibroTouch measurements in chronic hepatitis B patients based on liver pathology

DOI: 10.3969/j.issn.1001-5256.2019.02.019